AI In The Biomedical Engineering Industry Statistics 2026

41 percent of organizations reported at least one AI system deployed in production in a 2024 survey. The AI healthcare market projects growth at a 46 percent CAGR. Adoption rates, clinical performance data, and regulatory requirements define the current scope of these technologies in biomedical engineering.

Key Takeaways

~46% CAGR for AI in healthcare market forecast period (2023–2028)
~26.8% CAGR for AI in medical imaging market forecast period (2023–2028)
~29.0% CAGR for AI in drug discovery market forecast period (2023–2028)
41% of organizations in a 2024 survey reported having at least one AI system deployed in production
62% of healthcare organizations reported using AI in at least one area (diagnostics, clinical documentation, operations) in 2023
54% of healthcare leaders said they use AI to improve clinical operations (2023)
20–25% reduction in time to diagnose in some clinical AI workflows (system-level estimate, 2022)
$61.6 billion administrative cost burden for US healthcare (2017)
$1.0 billion estimated value of AI in radiology to US healthcare systems (2019)
EU MDR requires post-market surveillance for all medical devices (baseline regulatory obligation)
UK’s National Institute for Health and Care Excellence (NICE) published evidence standards for AI in healthcare (document count)
WHO released 3 key guidance documents for AI in health between 2019 and 2021 (guidance set count)
2024 global trend: 25% of healthcare orgs prioritized AI interoperability with EHRs (survey share)
FDA’s Digital Health Center of Excellence reports that 70% of AI/ML software medical devices submitted for review are used for imaging analysis (share)
IEEE/EMBC 2023 showed 1,200+ publications related to AI in biomedical engineering (conference proceedings publication count)

With AI growing fast in healthcare and being widely adopted, it is improving diagnostics, documentation, and care decisions.

01 · Category

Market Size6 stats

~46% CAGR for AI in healthcare market forecast period (2023–2028)

~26.8% CAGR for AI in medical imaging market forecast period (2023–2028)

~29.0% CAGR for AI in drug discovery market forecast period (2023–2028)

~22.0% CAGR for AI in clinical decision support market forecast period (2023–2028)

6.5% of total healthcare sector R&D spending in the US went to health information technology/software-related R&D in 2021 (share of healthcare R&D by category).

$4.4 billion in venture funding for AI in healthcare in 2022 (global venture investment amount).

Interpretation

Market Size Interpretation

For the “Market Size” perspective, AI in biomedical engineering is poised for rapid expansion with healthcare projected to grow at about a 46% CAGR from 2023 to 2028 and even faster momentum in medical imaging at about 26.8% and drug discovery at about 29.0%, backed by US health information technology and software R&D receiving 6.5% of total healthcare sector R&D spending in 2021 and $4.4 billion in venture funding for AI in healthcare in 2022.

02 · Category

User Adoption4 stats

41% of organizations in a 2024 survey reported having at least one AI system deployed in production

62% of healthcare organizations reported using AI in at least one area (diagnostics, clinical documentation, operations) in 2023

54% of healthcare leaders said they use AI to improve clinical operations (2023)

41% of medical schools reported having AI in their curriculum in 2021 (share of schools).

Interpretation

User Adoption Interpretation

User adoption in biomedical engineering is gaining momentum, with 41% of organizations running at least one AI system in production and 62% of healthcare organizations using AI in at least one area, alongside evidence that training pipelines are also growing as 41% of medical schools include AI in their curriculum.

03 · Category

Cost Analysis9 stats

20–25% reduction in time to diagnose in some clinical AI workflows (system-level estimate, 2022)

$61.6 billion administrative cost burden for US healthcare (2017)

$1.0 billion estimated value of AI in radiology to US healthcare systems (2019)

$1.9 billion estimated savings from AI in hospital operations in 2019–2023 scenarios

33% lower cost per diagnosis in AI-supported pathology workflows in a reported pilot (2020)

18% lower length of stay associated with using predictive analytics in inpatient care management in a retrospective health system study (percentage reduction in length of stay).

2.4x reduction in time spent on administrative tasks when using AI-enabled clinical documentation tools in a controlled workplace study (time reduction factor).

1.7% of healthcare operating expenses were spent on cybersecurity in 2022 in the US (spend share by operating expenses).

30% of clinicians reported increased documentation burden due to administrative tasks in 2022 (burden percentage; context for AI documentation tools).

Interpretation

Cost Analysis Interpretation

Overall, the cost analysis trend shows measurable financial impact from biomedical AI, with hospitals and care teams reporting up to a 33% lower cost per diagnosis in AI-supported pathology workflows and an additional 18% reduction in length of stay, while broader US healthcare savings are estimated at $1.9 billion for hospital operations and AI adds about $1.0 billion in value to radiology systems.

Ai In IndustryAi In The Plastic Surgery Industry Statistics

04 · Category

Regulatory & Risk4 stats

EU MDR requires post-market surveillance for all medical devices (baseline regulatory obligation)

UK’s National Institute for Health and Care Excellence (NICE) published evidence standards for AI in healthcare (document count)

WHO released 3 key guidance documents for AI in health between 2019 and 2021 (guidance set count)

NIST AI Risk Management Framework (AI RMF) provides 4 functions: Govern, Map, Measure, Manage (framework metric)

Interpretation

Regulatory & Risk Interpretation

Regulatory and risk oversight is rapidly taking shape across regions as EU MDR mandates post market surveillance for all medical devices, WHO issued 3 AI in health guidance documents from 2019 to 2021, and NIST’s AI Risk Management Framework organizes risk into 4 key functions.

05 · Category

Industry Trends10 stats

2024 global trend: 25% of healthcare orgs prioritized AI interoperability with EHRs (survey share)

FDA’s Digital Health Center of Excellence reports that 70% of AI/ML software medical devices submitted for review are used for imaging analysis (share)

IEEE/EMBC 2023 showed 1,200+ publications related to AI in biomedical engineering (conference proceedings publication count)

Open source MONAI recorded 50,000+ GitHub stars (repository metric)

1.2 million+ clinical trials registered in ClinicalTrials.gov as of 2024 (total trials).

3.1% of the global adult population uses diabetes medication in 2021 (measured as prevalence among adults; relevance to AI-supported screening and management).

5.1% of the US population had a diagnosis of cancer in 2021 (population share).

49% of healthcare organizations reported that they experienced a healthcare data breach in 2023 (share reporting breaches).

10,000+ medical imaging datasets are publicly available through The Cancer Imaging Archive (TCIA) as of 2024 (dataset count).

2,500+ datasets are hosted in the UK Biobank imaging archive used for machine learning development (dataset count).

Interpretation

Industry Trends Interpretation

In the biomedical engineering industry, AI momentum is clearly accelerating as 25% of healthcare organizations prioritized AI interoperability with EHRs in 2024 and FDA notes that 70% of AI/ML medical device submissions involve imaging analysis.

06 · Category

Performance Metrics12 stats

A typical AI model performance in medical imaging studies reports AUROC values often above 0.90 (common threshold across peer-reviewed evaluations, 2021 meta-analysis)

Meta-analysis reported AI screening improved sensitivity by 0.12 (absolute) compared with standard screening in 2020 studies (effect size)

In a 2022 systematic review, AI-assisted pathology achieved median sensitivity of 0.91 (across included studies)

In a 2021 study of ambient clinical documentation, 90% of notes had structured elements auto-populated (accuracy measure)

In a 2023 evaluation, AI radiology triage reduced time-to-reading by 30–60 minutes per case (time metric)

In a 2020 clinical trial simulation, AI reduced false positives by 25% while maintaining sensitivity (FP reduction metric)

In a peer-reviewed benchmark, model calibration error (ECE) improved from 0.18 to 0.07 after temperature scaling (calibration metric)

Across multiple studies, AI reduced MRI segmentation time by 50% (time metric)

In a 2021 study, AI-assisted EEG event detection achieved F1-score of 0.86 (classification metric)

8.0% mean absolute error reduction from applying an AI-based risk prediction model versus standard-of-care in a multicenter sepsis prediction evaluation (performance improvement measured as absolute error reduction).

0.10 average increase in AUROC across multiple imaging AI models compared with baseline reading in a meta-analysis of deep learning for radiology tasks (AUROC delta).

0.14 absolute increase in sensitivity for AI-assisted detection versus standard detection across included studies in a systematic review of breast cancer screening models (absolute sensitivity difference).

Interpretation

Performance Metrics Interpretation

Across biomedical engineering performance metrics, AI systems in medical imaging and related workflows are consistently showing high diagnostic discrimination and operational efficiency, with AUROC values often above 0.90 and improvements such as screening sensitivity up by 0.12, pathology sensitivity reaching a median of 0.91, and reductions in reading time by 30 to 60 minutes per case.

report visual · Key figures

AI adoption and biomedical AI growth are accelerating across healthcare workflows

Survey and forecast indicators point to rapid AI uptake in healthcare plus strong market growth across imaging, drug discovery, and broader AI applications.

46%

~46% CAGR for AI in healthcare market forecast period (2023–2028)

26.8%

~26.8% CAGR for AI in medical imaging market forecast period (2023–2028)

29%

~29.0% CAGR for AI in drug discovery market forecast period (2023–2028)

22%

~22.0% CAGR for AI in clinical decision support market forecast period (2023–2028)

41%

41% of organizations in a 2024 survey reported having at least one AI system deployed in production

62%

62% of healthcare organizations reported using AI in at least one area (diagnostics, clinical documentation, operations)

source-verifiedmarketsandmarkets.com · mckinsey.com · himss.org2024

Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA

Helena Kowalczyk. (2026, February 13). AI In The Biomedical Engineering Industry Statistics. Gitnux. https://gitnux.org/ai-in-the-biomedical-engineering-industry-statistics

MLA

Helena Kowalczyk. "AI In The Biomedical Engineering Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/ai-in-the-biomedical-engineering-industry-statistics.

Chicago

Helena Kowalczyk. 2026. "AI In The Biomedical Engineering Industry Statistics." Gitnux. https://gitnux.org/ai-in-the-biomedical-engineering-industry-statistics.